Breast cancer drug study looks at body fat changes
NCT ID NCT03697577
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at how three common breast cancer drugs (abemaciclib, ribociclib, or palbociclib) change body fat and muscle in 30 people with ER+/HER2- breast cancer that has spread. Participants get CT and DEXA scans before and after 24 weeks of treatment. The goal is to understand side effects on body composition, not to test if the drugs work.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Montefiore Medical Center
The Bronx, New York, 10461, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a radioactive tracer pinpoint Cancer's first stop?
- Can a personalized exercise program boost recovery in cancer survivors?
- Smartwatch could spot nerve damage before it starts
- Could ionized gas help fight breast cancer after surgery?
- Radiation may let breast cancer patients keep their nipple
- Can a smart digital program restore sleep for cancer survivors?